The Bull Case For AtaiBeckley (ATAI) Could Change Following Promising BPL-003 Phase 2b Depression Data

AtaiBeckley Inc. recently outlined its 2026 pipeline plans and presented new Phase 2b data for its BPL-003 nasal spray in treatment-resistant depression, which showed rapid, durable antidepressant ...
Hosted on MSN

Novel Agent for Major Depression Moves to Phase III, Even With Setback

Despite missing the primary endpoint, the novel K V 7 potassium channel opener azetukalner showed benefit in major depressive disorder (MDD) in the phase II, proof-of-concept, randomized X-NOVA trial.
Medscape

Esketamine Monotherapy Safe, Effective for Resistant Depression: Phase 4 Data

Esketamine monotherapy was associated with significantly alleviated symptoms of treatment-resistant depression (TRD) at day 28 compared to placebo in a new phase 4 trial. The research extends findings ...
Hosted on MSN

Biohaven’s phase II depression trial falls short, but analysts downplay impact – Wall Street looks ahead to epilepsy data

・Analyst Myles Minter noted that the company’s pivotal Phase III study of BHV-7000 in focal-onset epilepsy in the first half of 2026 will be the critical factor. ・Citi emphasized that the study was ...
Business Wire

Autobahn Therapeutics Announces Initiation of Phase 2 Trial of ABX-002 as an Adjunctive Treatment for Bipolar Depression

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the ...
MedPage Today

Novel Agent for Major Depression Moves to Phase III, Even With Setback

For patients with major depression, there was a clinically meaningful but not statistically significant improvement in the primary endpoint with 20-mg azetukalner. There were significant improvements ...